NASDAQ:CBIO - Catalyst Biosciences Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $10.91 -0.70 (-6.03 %) (As of 07/20/2018 06:59 AM ET)Previous Close$11.61Today's Range$10.65 - $11.3552-Week Range$3.11 - $37.00Volume1.06 million shsAverage Volume1.06 million shsMarket Capitalization$138.57 millionP/E RatioN/ADividend YieldN/ABeta2.35 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California. Receive CBIO News and Ratings via Email Sign-up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:CBIO CUSIP87611R30 Webwww.catalystbiosciences.com Phone650-266-8674 Debt Debt-to-Equity RatioN/A Current Ratio50.15 Quick Ratio50.15 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.02 million Price / Sales127.71 Cash FlowN/A Price / CashN/A Book Value$5.29 per share Price / Book2.06 Profitability EPS (Most Recent Fiscal Year)($7.45) Net Income$-21,560,000.00 Net Margins-2,983.40% Return on Equity-39.27% Return on Assets-34.64% Miscellaneous Employees13 Outstanding Shares11,940,000Market Cap$138.57 Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions What is Catalyst Biosciences' stock symbol? Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO." When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work? Shares of Catalyst Biosciences reverse split on the morning of Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split. How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences Inc (NASDAQ:CBIO) posted its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.59. The biopharmaceutical company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.23 million. Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 39.27%. View Catalyst Biosciences' Earnings History. When is Catalyst Biosciences' next earnings date? Catalyst Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Catalyst Biosciences. What price target have analysts set for CBIO? 2 brokerages have issued 12-month price targets for Catalyst Biosciences' stock. Their forecasts range from $12.50 to $35.00. On average, they expect Catalyst Biosciences' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 117.7% from the stock's current price. View Analyst Ratings for Catalyst Biosciences. What is the consensus analysts' recommendation for Catalyst Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Catalyst Biosciences' key competitors? Some companies that are related to Catalyst Biosciences include Merus (MRUS), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Depomed (DEPO), Evolus (EOLS), Arcus Biosciences (RCUS), ArQule (ARQL), Stemline Therapeutics (STML), Lannett (LCI), Magenta Therapeutics (MGTA), Aurinia Pharmaceuticals (AUPH), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), Synergy Pharmaceuticals (SGYP) and Zymeworks (ZYME). Who are Catalyst Biosciences' key executives? Catalyst Biosciences' management team includes the folowing people: Dr. Nassim Usman, Pres, CEO & Director (Age 58)Mr. Fletcher Payne, Chief Financial Officer (Age 55)Dr. Howard Levy, Chief Medical Officer (Age 64)Dr. Charles S. Craik, Co-Founder and Chairman of Scientific Advisory BoardMr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations Has Catalyst Biosciences been receiving favorable news coverage? News articles about CBIO stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalyst Biosciences earned a daily sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.26 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. How do I buy shares of Catalyst Biosciences? Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Catalyst Biosciences' stock price today? One share of CBIO stock can currently be purchased for approximately $10.91. How big of a company is Catalyst Biosciences? Catalyst Biosciences has a market capitalization of $138.57 million and generates $1.02 million in revenue each year. The biopharmaceutical company earns $-21,560,000.00 in net income (profit) each year or ($7.45) on an earnings per share basis. Catalyst Biosciences employs 13 workers across the globe. How can I contact Catalyst Biosciences? Catalyst Biosciences' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-8674 or via email at [email protected] MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 157 (Vote Outperform)Underperform Votes: 163 (Vote Underperform)Total Votes: 320MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?